Highlighted Prostate Cancer Trials and Studies  

Search for Prostate Cancer Clinical Trials

Prostate Cancer Research Studies in Chicago Area

Organ confined/localized

  • We are not aware of any trials in this category at this time

Locally advanced

Rising PSA post-initial treatment

Hormone refractory/hormone resistant

Hormone refractory/hormone resistant AND Metastatic:

Metastatic

Multiple trials


TRIAL DESCRIPTIONS

Prostate Cancer Research Studies in Chicago Area

  • Penile Rehabilitation 

    If you or someone you knows in the Chicago area had treatment for prostate cancer with surgery or radiation in the past 3 months and is interested in working on penile rehabilitation to preserve pre-treatment erectile function and you may also be eligible to participate in a research study using questionnaires to examine quality of life after prostate cancer treatment. To learn more about the penile rehabilitation program call 847-503-4245.

  • The Lived Experience of Men with Sexual Dysfunction after Prostate Cancer Treatment

    Researchers at NorthShore University HealthSystem want to learn how erectile dysfunction after prostate cancer treatment impacts quality of life of men and their partners. Participants complete a one-time interview with the study investigator or member of the research staff. Cancer survivors will also complete a one-time questionnaire about their symptoms and problems. If you are a man or partner of a man in the Chicago area who has undergone radical prostatectomy (surgery) or radiation therapy for prostate cancer at least 1 year ago and no more than 5 years ago you may be able to participate in the study. Call 847-503-4281 for more information. As part of Us TOO’s continued commitment to bring news of new interventions and treatments for the benefit of prostate cancer patients, we are pleased to share this news with you about the following opportunities to participate in clinical trials.



Organ confined/localized

  • We are not aware of any trials in this category at this time



Locally advanced

  • A Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy with Autologous Immature Dendritic Cells (VDC2008) in Chemo-naďve Men with Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone (The “CRITICAL” Trial)


  • The purpose of this study is to determine whether intra-tumoral injection of subject’s own dendritic cells after cryotherapy of the prostate is safe and effective in the treatment of advanced prostate cancer. In theory, injected dendritic cells will internalize antigens from tumor cells damaged by cryotherapy and facilitate the initiation of a tumor-specific immune response. Subjects will also receive a low dose regimen of cyclophophamide pre- and post- cryotherapy to selectively reduce number of regulatory T cells (Treg), which have been implicated in dampening or halting immune responses. Using this combination of therapies, it is thought that a clinically significant anti-cancer immune response might be elicited.

    Click Here for clinical trials.gov listing with more information about this study


Rising PSA post-initial treatment

  • Phase II Trial of an Adenovirus/PSA Vaccine for Recurrent Prostate Cancer [012010]

    The University of Iowa and the Iowa City VA Medical Center are conducting a Phase II trial of a vaccine for the treatment of recurrent prostate cancer. Two protocols are active; one protocol treats hormone naďve patients who have experienced a recent, but continued rise in their serum PSA following initial treatment for their prostate cancer, and a second protocol treats men with hormone refractory prostate cancer. The hypothesis is that the vaccine will induce the production of anti-PSA and, therefore, anti-prostate cancer, immune responses that will cause the destruction of the cancer cells anywhere in the body.

    Interested patients can contact the Clinical Trial Coordinator Ms. Pamela Zehr at 319-353-8914, pamela-zehr@uiowa.edu or Dr. David Lubaroff at 319-335-8423, david-lubaroff@uowa.edu.

    Click Here for clinicaltrials.gov listing with more information about this study

  • IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

    The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.

    Inclusion Criteria:

    • Currently receiving and must have had continuous therapy with Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months before screening, with a serum testosterone of < 50 nanograms/deciliter (< 2.0 nanograms per milliliter) or have undergone surgical removal of the testicles with a blood testosterone level of < 50 nanograms per deciliter (<2.0 nanograms per millimeter)

    • Have rising Prostate Specific Antigen (PSA) after local therapy and treatment with GnRH monotherapy (defined as a PSA of greater than or equal to 10 nanograms/milliliter obtained at screening or PSADT (prostate-specific antigen doubling time) of < or equal to 6 months with a baseline PSA of greater than or equal to 2.0 nanograms/milliliter)

    Exclusion Criteria:

    • Have prior or current evidence of local disease progression or metastatic disease as defined by modified response evaluation criteria in solid tumors (RECIST) criteria

    • Have received chemotherapy for treatment of castrate-resistant prostate cancer

    • Have a Prostate Specific Androgen Doubling Time (PSADT) of greater than 15 months

    http://www.clinicaltrials.gov/ct2/show/NCT01314118?term=prostate+cancer%2Cabiraterone&rank=19

  • The SPARTAN Study – A clinical research study for patients whose prostate cancer has not spread beyond the prostate is now enrolling




Hormone refractory/hormone resistant

  • Phase II Trial of an Adenovirus/PSA Vaccine for Recurrent Prostate Cancer [012010]

    The University of Iowa and the Iowa City VA Medical Center are conducting a Phase II trial of a vaccine for the treatment of recurrent prostate cancer. Two protocols are active; one protocol treats hormone naďve patients who have experienced a recent, but continued rise in their serum PSA following initial treatment for their prostate cancer, and a second protocol treats men with hormone refractory prostate cancer. The hypothesis is that the vaccine will induce the production of anti-PSA and, therefore, anti-prostate cancer, immune responses that will cause the destruction of the cancer cells anywhere in the body.

    Interested patients can contact the Clinical Trial Coordinator Ms. Pamela Zehr at 319-353-8914, pamela-zehr@uiowa.edu or Dr. David Lubaroff at 319-335-8423, david-lubaroff@uowa.edu.

    Click Here for clinicaltrials.gov listing with more information about this study

  •  

Hormone refractory/hormone resistant AND Metastatic:

  • 2 Metastatic PCa Studies for Investigational Oral Medication Now Enrolling Participants: Chemotherapy naive for metastatic disease and Post-Chemotherapy

    Two global research studies, called the elm•pc studies, are seeking men with metastatic castration-resistant prostate cancer to participate in the effort to evaluate a new investigational oral medication, TAK-700, given with prednisone.

    The studies will help determine if TAK-700, given with prednisone, can lengthen the lives of men with metastatic castration-resistant prostate cancer compared to prednisone alone.

    Men enrolled in either study will be assigned to one of two groups: those who will receive the investigational oral medication, TAK-700, with prednisone, and those who will be treated with prednisone alone. Prednisone is asteroid commonly used to treat advanced prostate cancer.

    TAK-700, an investigational oral lyase inhibitor, is being studied for individuals with metastatic prostate cancer.

    The elm•pc studies are being conducted by Millennium: The Takeda Oncology Company. To learn more about the elm•pc studies call 1-855-493-5672 or visit www.elmpctrials.com.


Metastatic

  • Ongoing enrollment for asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer (mCRPC) patients across as many as 250 clinical trial centers and up to 15 countries

    More information can be found on clinicaltrials.gov, or the study website www.continueyourfight.com

  • ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain [071108]

    InSightec Ltd. is conducting an FDA approved phase III pivotal study (BM004) to evaluate the effectiveness and safety of ExAblate (MR guided Focused Ultrasound, MRgFUS) for the palliation of pain from metastatic bone tumors in patients who are not suitable candidates to receive additional radiation therapy. ExAblate MRgFUS uses (focused) ultrasound to treat tissue without surgical cutting (i.e. non-invasive procedure). The ExAblate use for the palliation of pain from bone metastases is experimental. The study hypothesis is that ExAblate is safe and effective in the treatment of pain resulting from metastatic bone tumors in patients that did not respond to radiation treatment or who are otherwise unsuitable for radiation treatment, with a low incidence of co-morbidity.

    This clinical trial is open for enrollment at study sites nationwide. 

    Click Here for a study summary and a list of participating sites.
    Click Here for more information about the studies and about bone metastases

Multiple trials

  • Prostate cancer trials at the NIH Clinical Center in Bethesda, MD [080706]

    There is no charge for medical care received at the NIH Clinical Center. Study participants will be responsible for travel costs for their initial screening visits. Once participants are enrolled in a trial, NCI will pay for the transportation costs for all subsequent trial-related visits for participants who do not live in the local area. In addition, these participants will receive a small per diem for food and lodging expenses if they are being treated as outpatients.

    For more information on clinical trials conducted at NCI, please visit http://bethesdatrials.cancer.gov or call the Clinical Trials Referral Office (formerly Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937). 

    The National Cancer Institute also sponsors clinical studies at cancer centers nationwide. To learn more about these studies, call 1-800-4-CANCER (1-800-422-6237).



 
 

Facebook - UsToo.org  Twitter - UsToo.org  LinkedIn - UsToo.org Inspire prostate cancer discussions – UsToo.org 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

 
Copyright © 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.